Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
Epilepsy Behav ; 122: 108198, 2021 09.
Artículo en Inglés | MEDLINE | ID: mdl-34284219

RESUMEN

Dravet syndrome (DS) is an intractable developmental and epileptic encephalopathy significantly impacting affected children and their families. A novel, one-time, adeno-associated virus (AAV)-mediated gene regulation therapy was designed to treat the underlying cause of DS, potentially improving the full spectrum of DS manifestations. To ensure the first-in-human clinical trial addresses meaningful outcomes for patients and families, we examined their perspectives, priorities, goals, and desired outcomes in the design phase through a mixed methods approach (quantitative and qualitative). We conducted a non-identifiable parent caregiver survey, shared through a patient advocacy organization (n = 36 parents; children age ≤6 years). Parents were also engaged via three group discussions (n = 10; children age 2-20 years) and optional follow-up in-depth individual interviews (n = 6). Qualitative data analysis followed an inductive interpretive process, and qualitative researchers conducted a thematic analysis with a narrative approach. Survey results revealed most children (94%) were diagnosed by age 1, with onset of seizures at mean age 6.2 months and other DS manifestations before 2 years. The most desired disease aspects to address with potential new disease-modifying therapies were severe seizures (ranked by 92% of caregivers) and communication issues (development, expressive, receptive; 72-83%). Qualitative results showed the need for trial outcomes that recognize the impact of DS on the whole family. Parents eventually hope for trials including children of all ages and were both excited about the potential positive impact of a one-time disease-modifying therapy and mindful of potential long-term implications. Participants reflected on the details and risks of a clinical trial design (e.g., sham procedures) and described the different factors that relate to their decision to participate in a trial. Their main aspirations were to stop neurodevelopmental stagnation, to reduce seizures, and to reduce the impact on their families' wellbeing. To our knowledge, this is the first study within a patient-oriented research framework that specifically explored parents' needs and perceptions regarding clinical trials of a potential disease-modifying therapy for children with a severe, developmental disease, such as DS.


Asunto(s)
Epilepsias Mioclónicas , Síndromes Epilépticos , Espasmos Infantiles , Adolescente , Adulto , Cuidadores , Niño , Preescolar , Epilepsias Mioclónicas/genética , Epilepsias Mioclónicas/terapia , Humanos , Lactante , Padres , Adulto Joven
2.
Paediatr Child Health ; 21(4): e32-8, 2016 May.
Artículo en Inglés | MEDLINE | ID: mdl-27429578

RESUMEN

Medical errors are common within paediatrics; however, little research has examined the process of disclosing medical errors in paediatric settings. The present systematic review of current research and policy initiatives examined evidence regarding the disclosure of medical errors involving paediatric patients. Peer-reviewed research from a range of scientific journals from the past 10 years is presented, and an overview of Canadian and international policies regarding disclosure in paediatric settings are provided. The purpose of the present review was to scope the existing literature and policy, and to synthesize findings into an integrated and accessible report. Future research priorities and policy implications are then identified.


Les erreurs médicales sont courantes en pédiatrie. Cependant, peu de recherches abordent leur processus de divulgation en milieu pédiatrique. La présente analyse systématique des projets de recherche et de politique les plus récents a porté sur les données probantes relatives à la divulgation des erreurs médicales auprès de patients d'âge pédiatrique. Les recherches révisées par les pairs tirées d'une série de revues scientifiques des dix dernières années sont présentées, de même qu'un aperçu des politiques canadiennes et internationales sur la divulgation en milieu pédiatrique. La présente analyse visait à évaluer les publications et les politiques existantes et à synthétiser les résultats dans un rapport intégré et accessible. Les prochaines priorités de la recherche et leurs conséquences sur les politiques sont ensuite exposées.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA